By Professor Richard Bryan Lock

Journal articles

Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR, 2020, 'PIM kinase inhibitors block the growth of primary T-cell acute lymphoblastic leukemia: Resistance pathways identified by network modeling analysis', Molecular Cancer Therapeutics, 19, pp. 1809 - 1821, http://dx.doi.org/10.1158/1535-7163.MCT-20-0160

Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV, 2020, 'OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis', Leukemia, 34, pp. 1828 - 1839, http://dx.doi.org/10.1038/s41375-019-0692-5

Toscan CE; Jing D; Mayoh C; Lock RB, 2020, 'Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression', British Journal of Cancer, 122, pp. 1769 - 1781, http://dx.doi.org/10.1038/s41416-020-0824-8

Somers K; Evans K; Cheung L; Karsa M; Pritchard T; Kosciolek A; Bongers A; El-Ayoubi A; Forgham H; Middlemiss S; Mayoh C; Jones L; Gupta M; Kees UR; Chernova O; Korotchkina L; Gudkov AV; Erickson SW; Teicher B; Smith MA; Norris MD; Haber M; Lock RB; Henderson MJ, 2020, 'Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia', Leukemia, 34, pp. 1524 - 1539, http://dx.doi.org/10.1038/s41375-019-0683-6

Xie J; Span M; van Maarseveen E; Langenhorst J; Boddy AV; Sia KCS; Sutton R; Venn N; Punt AM; Tyrrell V; Haber M; Trahair T; Lau L; Marshall GM; Lock RB, 2020, 'Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia', Pediatric Blood and Cancer, 67, pp. e28133, http://dx.doi.org/10.1002/pbc.28133

Connerty P; Lock RB; de Bock CE, 2020, 'Long Non-coding RNAs: Major Regulators of Cell Stress in Cancer', Frontiers in Oncology, 10, http://dx.doi.org/10.3389/fonc.2020.00285

McCalmont H; Li KL; Jones L; Toubia J; Bray SC; Casolari DA; Mayoh C; Samaraweera SE; Lewis ID; Prinjha RK; Smithers N; Wang S; Lock RB; D’Andrea RJ, 2020, 'Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia', Blood Advances, 4, pp. 296 - 300, http://dx.doi.org/10.1182/bloodadvances.2019000586

Krivtsov AV; Evans K; Gadrey JY; Eschle BK; Hatton C; Uckelmann HJ; Ross KN; Perner F; Olsen SN; Pritchard T; McDermott L; Jones CD; Jing D; Braytee A; Chacon D; Earley E; McKeever BM; Claremon D; Gifford AJ; Lee HJ; Teicher BA; Pimanda JE; Beck D; Perry JA; Smith MA; McGeehan GM; Lock RB; Armstrong SA; Chacon Fajardo D, 2019, 'A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia', Cancer Cell, 36, pp. 660 - 673.e11, http://dx.doi.org/10.1016/j.ccell.2019.11.001

Rokita JL; Rathi KS; Cardenas MF; Upton KA; Jayaseelan J; Cross KL; Pfeil J; Egolf LE; Way GP; Farrel A; Kendsersky NM; Patel K; Gaonkar KS; Modi A; Berko ER; Lopez G; Vaksman Z; Mayoh C; Nance J; McCoy K; Haber M; Evans K; McCalmont H; Bendak K; Böhm JW; Marshall GM; Tyrrell V; Kalletla K; Braun FK; Qi L; Du Y; Zhang H; Lindsay HB; Zhao S; Shu J; Baxter P; Morton C; Kurmashev D; Zheng S; Chen Y; Bowen J; Bryan AC; Leraas KM; Coppens SE; Doddapaneni HV; Momin Z; Zhang W; Sacks GI; Hart LS; Krytska K; Mosse YP; Gatto GJ; Sanchez Y; Greene CS; Diskin SJ; Vaske OM; Haussler D; Gastier-Foster JM; Kolb EA; Gorlick R; Li XN; Reynolds CP; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Raman P; Wheeler DA; Maris JM, 2019, 'Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design', Cell Reports, 29, pp. 1675 - 1689.e9, http://dx.doi.org/10.1016/j.celrep.2019.09.071

Jones L; McCalmont H; Evans K; Mayoh C; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB, 2019, 'Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts', Pediatric Blood and Cancer, 66, pp. e27765, http://dx.doi.org/10.1002/pbc.27765

Mosse YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ, 2019, 'A phase II study of alisertib in children with recurrent/refractory solid tumors or leukemia: Children's Oncology Group Phase I and pilot Consortium (ADVL0921)', Clinical Cancer Research, 25, pp. 3229 - 3238, http://dx.doi.org/10.1158/1078-0432.CCR-18-2675

de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF, 2019, 'T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development', Haematologica, 104, pp. e204 - e207, http://dx.doi.org/10.3324/haematol.2018.198424

Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua G-A; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS, 2019, 'Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.', Haematologica, 104, pp. e300 - e303, http://dx.doi.org/10.3324/haematol.2018.192906

Evans K; Duan JX; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB, 2019, 'OBI-3424, a novel AKR1c3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL', Clinical Cancer Research, 25, pp. 4493 - 4503, http://dx.doi.org/10.1158/1078-0432.CCR-19-0551

Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ; Bongers A, 2019, 'Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia', International Journal of Cancer, 146, pp. 1902 - 1916, http://dx.doi.org/10.1002/ijc.32582

Bayat N; McOrist N; Ariotti N; Lai M; Sia KCS; Li Y; Grace JL; Quinn JF; Whittaker MR; Kavallaris M; Davis TP; Lock RB, 2019, 'Thiol-reactive star polymers functionalized with short ethoxy-containing moieties exhibit enhanced uptake in acute lymphoblastic leukemia cells', International Journal of Nanomedicine, 14, pp. 9795 - 9808, http://dx.doi.org/10.2147/IJN.S220326

Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB, 2018, 'Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia', Cancer Cell, 34, pp. 906 - 921.e8, http://dx.doi.org/10.1016/j.ccell.2018.11.002

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KM; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'The Avatar Acceptability Study: Survivor, Parent and Community Willingness to Use Patient-Derived Xenografts to Personalize Cancer Care', EBioMedicine, 37, pp. 205 - 213, http://dx.doi.org/10.1016/j.ebiom.2018.10.060

Wakefield CE; Doolan EL; Fardell JE; Signorelli C; Quinn VF; Tucker KF; Patenaude AF; Marshall GM; Lock RB; Georgiou G; Cohn RJ, 2018, 'Protocol for the avatar acceptability study: A multiperspective cross-sectional study evaluating the acceptability of using patient-derived xenografts to guide personalised cancer care in Australia and New Zealand', BMJ Open, 8, pp. e024064, http://dx.doi.org/10.1136/bmjopen-2018-024064

McClure BJ; Heatley SL; Kok CH; Sadras T; An J; Hughes TP; Lock RB; Yeung D; Sutton R; White DL, 2018, 'Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression', British Journal of Cancer, 118, pp. 1000 - 1004, http://dx.doi.org/10.1038/s41416-018-0022-0

Jones L; Richmond J; Evans K; Carol H; Jing D; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB, 2017, 'Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL', Clinical Cancer Research, 23, pp. 3744 - 3755, http://dx.doi.org/10.1158/1078-0432.CCR-16-2392

Brumatti G; Ma C; Lalaoui N; Nguyen N-Y; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2017, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia (vol 8, 339ra69, 2016)', SCIENCE TRANSLATIONAL MEDICINE, 9, http://dx.doi.org/10.1126/scitranslmed.aan8181

Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2017, 'Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 64, pp. e26263, http://dx.doi.org/10.1002/pbc.26263

Kurmasheva RT; Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Kang M; Reynolds CP; Wu J; Houghton PJ; Smith MA, 2017, 'Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 64, pp. e26304, http://dx.doi.org/10.1002/pbc.26304

Jones L; Carol H; Evans K; Richmond J; Houghton PJ; Smith MA; Lock RB, 2016, 'A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program', Leukemia, 30, pp. 2133 - 2141, http://dx.doi.org/10.1038/leu.2016.192

Murphy B; Yin H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Kurmasheva RT; Dvorchik I; Wu J; Billups CA; Boateng N; Smith MA; Lock RB; Houghton PJ, 2016, 'Evaluation of alternative in vivo drug screening methodology: A single mouse analysis', Cancer Research, 76, pp. 5798 - 5809, http://dx.doi.org/10.1158/0008-5472.CAN-16-0122

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 63, pp. 1744 - 1752, http://dx.doi.org/10.1002/pbc.26064

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Correction: Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics (Cancer Cell (2016) 30(3) (499–500) (S1535610816000350) (10.1016/j.ccell.2016.01.006))', Cancer Cell, 30, pp. 499 - 500, http://dx.doi.org/10.1016/j.ccell.2016.08.009

Khaw SL; Suryani S; Evans K; Richmond J; Robbins A; Kurmasheva RT; Billups CA; Erickson SW; Guo Y; Houghton PJ; Smith MA; Carol H; Roberts AW; Huang DCS; Lock RB, 2016, 'Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia', Blood, 128, pp. 1382 - 1395, http://dx.doi.org/10.1182/blood-2016-03-707414

Trahair TN; Lock RB; Sutton R; Sia KCS; Evans K; Richmond J; Law T; Venn NC; Irving JA; Moore S; Nievergall E; Dang P; Heatley SL; White DL; Revesz T, 2016, 'Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL', Bone Marrow Transplantation, 51, pp. 1279 - 1282, http://dx.doi.org/10.1038/bmt.2016.122

Richmond J; Robbins A; Evans K; Beck D; Kurmasheva RT; Billups CA; Carol H; Heatley S; Sutton R; Marshall GM; White D; Pimanda J; Houghton PJ; Smith MA; Lock RB, 2016, 'Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant', Cancer Research, 76, pp. 4579 - 4591, http://dx.doi.org/10.1158/0008-5472.CAN-16-0523

Huang Y; Thoms JAI; Tursky ML; Knezevic K; Beck D; Chandrakanthan V; Suryani S; Olivier J; Boulton A; Glaros EN; Thomas SR; Lock RB; MacKenzie KL; Bushweller JH; Wong JWH; Pimanda JE, 2016, 'MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation', Leukemia, 30, pp. 1552 - 1561, http://dx.doi.org/10.1038/leu.2016.55

Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; De Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J, 2016, 'The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia', Science Translational Medicine, 8, http://dx.doi.org/10.1126/scitranslmed.aad3099

Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T, 2016, 'The bromodomain inhibitor jq1 and the histone deacetylase inhibitor panobinostat synergistically reduce n-myc expression and induce anticancer effects', Clinical Cancer Research, 22, pp. 2534 - 2544, http://dx.doi.org/10.1158/1078-0432.CCR-15-1666

Dolai S; Sia KCS; Robbins AK; Zhong L; Heatley SL; Vincent TL; Hochgräfe F; Sutton R; Kurmasheva RT; Revesz T; White DL; Houghton PJ; Smith MA; Teachey DT; Daly RJ; Raftery MJ; Lock RB, 2016, 'Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia', Cancer Research, 76, pp. 2766 - 2777, http://dx.doi.org/10.1158/0008-5472.CAN-15-2786

Churchman ML; Evans K; Richmond J; Robbins A; Jones L; Shapiro IM; Pachter JA; Weaver DT; Houghton PJ; Smith MA; Lock RB; Mullighan CG, 2016, 'Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL', JCI Insight, 1, pp. e86082, http://dx.doi.org/10.1172/jci.insight.86082

Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 63, pp. 443 - 450, http://dx.doi.org/10.1002/pbc.25826

Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW, 2016, 'The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid Leukemia', Cancer Research, 76, pp. 1158 - 1169, http://dx.doi.org/10.1158/0008-5472.CAN-15-1070

Lalaoui N; Hänggi K; Brumatti G; Chau D; Nguyen NYN; Vasilikos L; Spilgies LM; Heckmann DA; Ma C; Ghisi M; Salmon JM; Matthews GM; de Valle E; Moujalled DM; Menon MB; Spall SK; Glaser SP; Richmond J; Lock RB; Condon SM; Gugasyan R; Gaestel M; Guthridge M; Johnstone RW; Munoz L; Wei A; Ekert PG; Vaux DL; Wong WWL; Silke J, 2016, 'Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics', Cancer Cell, 29, pp. 145 - 158, http://dx.doi.org/10.1016/j.ccell.2016.01.006

Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program', Pediatric Blood and Cancer, 63, pp. 276 - 286, http://dx.doi.org/10.1002/pbc.25727

El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB, 2016, 'A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts', Oncotarget, 7, pp. 60475 - 60490, http://dx.doi.org/10.18632/oncotarget.11125

Smith AM; Dun MD; Lee EM; Harrison C; Kahl R; Flanagan H; Panicker N; Mashkani B; Don AS; Morris J; Toop H; Lock RB; Powell JA; Thomas D; Guthridge MA; Moore A; Ashman LK; Skelding KA; Enjeti A; Verrills NM, 2016, 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7, pp. 47465 - 47478, http://dx.doi.org/10.18632/oncotarget.10167

Yadav BD; Samuels AL; Wells JE; Sutton R; Venn NC; Bendak K; Anderson D; Marshall GM; Cole CH; Beesley AH; Kees UR; Lock RB, 2016, 'Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia', Oncotarget, 7, pp. 58728 - 58742, http://dx.doi.org/10.18632/oncotarget.11233

Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA, 2016, 'Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, http://dx.doi.org/10.1002/pbc.26064

Manesh DM; El-Hoss J; Evans K; Richmond J; Toscan CE; Bracken LS; Hedrick A; Sutton R; Marshall GM; Wilson WR; Kurmasheva RT; Billups C; Houghton PJ; Smith MA; Carol H; Lock RB, 2015, 'AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia', Blood, 126, pp. 1193 - 1202, http://dx.doi.org/10.1182/blood-2014-12-618900

Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; We A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB, 2015, 'Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice', Haematologica, 100, pp. 914 - 926, http://dx.doi.org/10.3324/haematol.2014.113092

Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB, 2015, 'Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts', Organic and Biomolecular Chemistry, 13, pp. 6299 - 6312, http://dx.doi.org/10.1039/c5ob00779h

Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA, 2015, 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, 62, pp. 1106 - 1109, http://dx.doi.org/10.1002/pbc.25329

Tursky ML; Beck D; Thoms JAI; Huang Y; Kumari A; Unnikrishnan A; Knezevic K; Evans K; Richards LA; Lee E; Morris J; Goldberg L; Izraeli S; Wong JWH; Olivier J; Lock RB; MacKenzie KL; Pimanda JE, 2015, 'Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias', Leukemia, 29, pp. 819 - 827, http://dx.doi.org/10.1038/leu.2014.299

Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB, 2015, 'Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia', Clinical Cancer Research, 21, pp. 1395 - 1405, http://dx.doi.org/10.1158/1078-0432.CCR-14-2300

Back to profile page